![](/images/Company_Logo/company_logo_default.png)
Achieve Life Sciences Inc Profile last edited on: 12/2/2023
CAGE: 8GZH3
UEI: JJKEN12FWSJ3
Business Identifier: Enabling effective smoking cessation Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 01
County: King
Congr. District: 01
County: King
Public Profile
Achieve Life Sciences is a specialty pharmaceutical company structured around addressing the global smoking health and nicotine addiction epidemic through development and commercialization of cytisinicline. Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the ?4?2 nicotine receptor. Over the past 20 years, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. Achieves focus is to address the global smoking health epidemic by making cytisinicline widely available.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : ACHVIP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $2,817,896 | |
Project Title: Benefit and Safety of Cytisinicline (cytisine) for Cessation of Nicotine E-cigarette Use |
Key People / Management
John Bencich -- Chief Executive Officer
Cindy Jacobs -- President and Chief Medical Officer
Anthony Clarke -- Chief Scientific Officer
Richard Stewart -- Executive Chairman of the Board of Directors
Jaime Xinos -- Executive VP Commercial
Cindy Jacobs -- President and Chief Medical Officer
Anthony Clarke -- Chief Scientific Officer
Richard Stewart -- Executive Chairman of the Board of Directors
Jaime Xinos -- Executive VP Commercial
Company News
There are no news available.